AbbVie Sees Solid Japan Outlook Despite 2020 Dip
Multi-Indication Pipeline
AbbVie expects double-digit sales growth in Japan over the mid-term despite a decline last year, driven in large part by multi-indication plans for new products.
AbbVie expects double-digit sales growth in Japan over the mid-term despite a decline last year, driven in large part by multi-indication plans for new products.